Jimin M. Gao

Wenzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

NF-κB/NFAT signaling contributes to B7-H3 TRuC-T cell cytotoxicity and supports a reporter platform for glioblastoma immunotherapy.

NF-κB/NFAT signaling contributes to B7-H3 TRuC-T cell cytotoxicity and supports a reporter platform for glioblastoma immunotherapy.

Journal: Frontiers in immunology

Published: May 09, 2026

Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma.

Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma.

Journal: Frontiers in immunology

Published: September 27, 2024

NECTIN-4-redirected T cell Antigen Coupler T cells bearing CD28 show superior antitumor responses against solid tumors.

NECTIN-4-redirected T cell Antigen Coupler T cells bearing CD28 show superior antitumor responses against solid tumors.

Journal: Frontiers in immunology

Published: June 28, 2024

Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 04, 2023

Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells

Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells

Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Published: July 05, 2023

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma.

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma.

Journal: Cell discovery

Published: June 25, 2023

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.

Journal: Frontiers in immunology

Published: May 31, 2022

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells.

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells.

Journal: Frontiers in oncology

Published: March 10, 2022

Biofabricated macrophage and fibroblast membranes synergistically promote skin wound healing.

Biofabricated macrophage and fibroblast membranes synergistically promote skin wound healing.

Journal: Bioengineering & translational medicine

Published: November 22, 2021

Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma

Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: July 21, 2021

TNFα antagonist in combination with PD-1 blocker to prevent or retard malignant transformation of B[a]P-induced chronic lung inflammation.

TNFα antagonist in combination with PD-1 blocker to prevent or retard malignant transformation of B[a]P-induced chronic lung inflammation.

Journal: Carcinogenesis

Published: July 20, 2021

Construction of CAR-T cells targeting CS1 and analysis of their antitumor activity in vitro

Construction of CAR-T cells targeting CS1 and analysis of their antitumor activity in vitro

Journal: Sheng wu gong cheng xue bao = Chinese journal of biotechnology

Published: November 10, 2020

Showing 1-12 of 114

Last Updated: 09/26/2026